FOR IMMEDIATE RELEASE CONTACT: John Truscott/Dennis Schornack

December 5, 1995 (517) 335- 6397/(517) 335-6847


Engler Orders Privatization of Biologic Products Division


Governor John Engler announced today that he has signed Executive Order 1995-25, which removes the Biologic Products Division from the Michigan Department of Public Health and establishes it as an autonomous, temporary two-year agency to be known as the Michigan Biologic Products Institute.

All of the duties, responsibilities, facilities, licenses and personnel previously associated with the Division are transferred to the Institute. The current Division Chief and Responsible Head of Manufacturing becomes the Director of the Institute and will report to a three-member Michigan Biologic Products Commission. The Commission is responsible for determining the fair-market value of the Institute's assets and for developing a plan to move the Institute out of state government and into the private sector within two years.

The Biologic Products Division has long played a role for the state in protecting Michigan's children from disease by manufacturing and distributing vaccines to prevent diphtheria, tetanus and pertussis (DTP), three of the nine pediatric diseases for which immunization is required under Michigan law. However, privatizing the Division offers the opportunity for a more efficient and effective approach, Engler said.

"Recent changes in the market for pediatric vaccines, and the growth of the Division's relationships with customers other than the State of Michigan have led me to conclude that the Division no longer fulfills a state government function and can become a self-sustaining private enterprise," the Governor stated.

Engler cited specific reasons for privatization:

Earlier this fall, Engler asked Acting Director of Public Health Jim Haveman to develop a comprehensive strategy to increase infant immunization rates to achieve 90 percent coverage by the year 2000.

"This is another important step in the process of privatizing this function," Haveman said. "We have been moving steadily in that direction for a number of years, and it has become increasingly clear that the manufacture and sale of biological products truly belongs in the private sector."

The move frees taxpayers of approximately $2.8 million in annual operating support that the Biological Products Division required, Haveman said.